Showing results (21-30 of 331) with videos related to
Sort By:
Pageof 34
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 26, 2018
Class Matters: Sensitivity of BRAF-Mutant Melanoma to MAPK InhibitionDouglas B Johnson, Kimberly B DahlmanThe Journal of Clinical Endocrinology and Metabolism|December 9, 2022
Approach to the Patient With Immune Checkpoint Inhibitor-Associated Endocrine DysfunctionJordan J Wright, Douglas B JohnsonExpert Review of Anticancer Therapy|January 28, 2021
Pembrolizumab in the adjuvant treatment of melanoma: efficacy and safetyCaroline A Nebhan, Douglas B JohnsonCancer Journal (Sudbury, Mass.)|March 25, 2024
Investigational Approaches for Treatment of Melanoma Patients Progressing After Standard of CareKylie A Fletcher, Douglas B JohnsonExpert Review of Clinical Immunology|June 5, 2023
Updates in toxicities associated with immune checkpoint inhibitorsNina B Curkovic, Douglas B JohnsonMed (New York, N.Y.)|May 19, 2022
Primed for toxicity: CD4+ T cells and immune checkpoint inhibitorsDouglas B Johnson, Justin M BalkoCurrent Treatment Options in Oncology|February 20, 2013
Update on the targeted therapy of melanomaDouglas B Johnson, Jeffrey A SosmanCancer Cell|March 3, 2023
T cell dynamism and immune-related adverse eventsDouglas B Johnson, Justin M BalkoExpert Review of Anticancer Therapy|January 31, 2020
Predictive biomarkers of response to immune checkpoint inhibitors in melanomaCaroline A Nebhan, Douglas B JohnsonCurrent Treatment Options in Oncology|February 28, 2021
Defining and Targeting BRAF Mutations in Solid TumorsBriana R Halle, Douglas B JohnsonPageof 34